Cargando…

Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?

Detalles Bibliográficos
Autores principales:	Mehta, Puja, Taylor, Peter C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Mediterranean Journal of Rheumatology (MJR) 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361185/ https://www.ncbi.nlm.nih.gov/pubmed/32676569 http://dx.doi.org/10.31138/mjr.31.1.112

Ejemplares similares

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

JAK/STAT pathway in pathology of rheumatoid arthritis (Review)
por: Ciobanu, Dana Alexandra, et al.
Publicado: (2020)

Could Polyphenols Help in the Control of Rheumatoid Arthritis?
por: Sung, Siyun, et al.
Publicado: (2019)

Could Nanotheranostics be the Answer to the Coronavirus Crisis?
por: Mosselhy, Dina A., et al.
Publicado: (2021)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
por: Malemud, Charles J.
Publicado: (2017)

Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
por: Angelini, Jacopo, et al.
Publicado: (2020)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington, Robert, et al.
Publicado: (2020)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis
por: Salaffi, Fausto, et al.
Publicado: (2022)

Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
por: Kotyla, Przemysław J., et al.
Publicado: (2020)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Could DIZE be the answer to COVID-19?
por: Qaradakhi, Tawar, et al.
Publicado: (2020)

Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis?
por: Lanchais, Kassandra, et al.
Publicado: (2020)

SNAREs: Could They be the Answer to an Energy Landscape Riddle in Exocytosis?
por: Liu, Wei, et al.
Publicado: (2010)

Metabolic Profiling of Rheumatoid Arthritis Neutrophils Reveals Altered Energy Metabolism That Is Not Affected by JAK Inhibition
por: Chokesuwattanaskul, Susama, et al.
Publicado: (2022)

VEGF and imaging of vessels in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2002)

Could ketamine be the answer to treating treatment-resistant major depressive disorder?
por: Ramadan, Abdullah Mohammed, et al.
Publicado: (2020)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus?
por: Flynn, Jacqueline K., et al.
Publicado: (2019)

Immunotherapy could be answer to treating novel coronavirus
Publicado: (2013)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
por: Moura, Rita A., et al.
Publicado: (2021)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
por: Mehta, Puja, et al.
Publicado: (2020)

Usability testing of ANSWER: a web-based methotrexate decision aid for patients with rheumatoid arthritis
por: Li, Linda C, et al.
Publicado: (2013)

Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity
por: Ptacek, Jason, et al.
Publicado: (2021)

Chrysoeriol suppresses hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes and inhibits JAK2/STAT3 signaling
por: Wu, Jia-Ying, et al.
Publicado: (2022)

JAK Inhibition in Patients with Rheumatoid Arthritis: Haemodynamic Effects and Impact on Micro- and Macrovascular Function. Study Design and Rationale
por: Anyfanti, Panagiota, et al.
Publicado: (2022)

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
por: Pei, Heying, et al.
Publicado: (2018)

Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
por: Dénarié, Delphine, et al.
Publicado: (2014)

Types of pain and their psychosocial impact in women with rheumatoid arthritis
por: Chancay, Maria Gabriela, et al.
Publicado: (2019)

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
por: Nagarakanti, Sandhya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_642qq4b43urhe222amfh4i6mbi